It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tamoxifen and raloxifene belong to a group of selective estrogen receptor modulators (SERMs). Their features and therapeutic effects depend on tissue and hormonal environment in which they are acting. Advantages resulting from selectivity are used in treatment and prevention of breast cancer and osteoporosis. However, side effects of these therapies should not be neglected. The most common negative symptoms of SERMs treatment are endometrial hyperplasia and cancer, hot flashes, night sweats, vaginal atrophy, dyspareunia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer